A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis

Biologics: Targets and Therapy

Volumn 4, Issue , 2010, Pages 33-44

  Myers, Stephen P ^a   O'Connor, Joan ^a   Fitton, J Helen ^b   Brooks, Lyndon ^a   Rolfe, Margaret ^a   Connellan, Paul ^a   Wohlmuth, Hans ^a   Cheras, Phil A ^a   Morris, Carol ^a  

^a SOUTHERN CROSS UNIVERSITY   (Australia)

^b Marinova Pty Ltd   (Australia)

Author keywords

Complementary medicine; Fucoidan; Inflammation; Osteoarthritis; TNF alpha

Indexed keywords

ANTIRHEUMATIC AGENT; CREATININE; ELECTROLYTE; LIPID; MANGANESE; PARACETAMOL; PYRIDOXINE; SEAWEED EXTRACT NUTRIENT COMPLEX; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREA; ZINC;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; CLINICAL TRIAL; COMPREHENSIVE ARTHRITIS TEST SCORE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FEMALE; FUCUS; FUCUS VESICULOSIS; HEMATOPOIESIS; HUMAN; JOINT STIFFNESS; KIDNEY FUNCTION; KNEE OSTEOARTHRITIS; LAMINARIA; LAMINARIA JAPONICA; LIPID BLOOD LEVEL; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; MACROCYSTIS; MACROCYSTIS PYRIFERA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NEPHROTOXICITY; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; UREA BLOOD LEVEL;

EID: 77951149514     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s8354     Document Type: Article

References (32)

1. March LM, Bagga H. Epidemiology of osteoarthritis in Australia. Med J Aust. 2004;180(5 Suppl):S6-S10.
2. Issa SN, Sharma L. Epidemiology of osteoarthritis: an update. Curr Rheumatol Rep. 2006;8(1):7-15.
3. Murphy L, Schwartz TA, Helmick CG, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59(9):1207-1213.
4. Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res. 2004;(427 Suppl): S6-S15.
5. Fajardo M, Di Cesare PE. Disease-modifying therapies for osteoarthritis: current status. Drugs Aging. 2005;22(2):141-161.
6. Frech TM, Clegg DO. The utility of nutraceuticals in the treatment of osteoarthritis. Curr Rheumatol Rep. 2007;9(1):25-30.
7. Ameye LG, Chee WS. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther. 2006;8(4):R127.
8. Frestedt JL, Walsh M, Kuskowski MA, Zenk JL. A natural mineral supplement provides relief from knee osteoarthritis symptoms: a randomized controlled pilot trial. Nutr J. 2008;7:9.
9. Cisar P, Jany R, Waczulikova I, et al. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytother Res. 2008;22(8):1087-1092.
10. Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85.
11. Brien S, Lewith GT, McGregor G. Devil's Claw (Harpagophytum procumbens) as a treatment for osteoarthritis: a review of efficacy and safety. J Altern Complement Med. 2006;12(10):981-993.
12. Huang TH, Tran VH, Duke RK, et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol. 2006;104(1-2): 149-155.
13. Shin HC, Hwang HJ, Kang KJ, Lee BH. An antioxidative and antiinflammatory agent for potential treatment of osteoarthritis from Ecklonia cava. Arch Pharm Res. 2006;29(2):165-171.
14. Grieve M. A Modern Herbal. Harmondsworth, Middlesex, England: Penguin Books Ltd; 1977.
15. Li B, Lu F, Wei X, Zhao R. Fucoidan: structure and bioactivity. Molecules. 2008;13(8):1671-1695.
16. Kusaykin M, Bakunina I, Sova V, et al. Structure, biological activity, and enzymatic transformation of fucoidans from the brown seaweeds. Biotechnol J. 2008;3(7):904-915.
17. Irhimeh MR, Fitton JH, Lowenthal RM, Kongtawelert P. A quantitative method to detect fucoidan in human plasma using a novel antibody. Methods Find Exp Clin Pharmacol. 2005;27(10):705-710.
18. Cumashi A, Ushakova NA, Preobrazhenskaya ME, et al. A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. Glycobiology. 2007;17(5):541-552.
19. Ritter LS, Copeland JG, McDonagh PF. Fucoidin reduces coronary microvascular leukocyte accumulation early in reperfusion. Ann Thorac Surg. 1998;66(6):2063-2071; discussion 2072.
20. Zaragoza MC, Lopez D, M PS, et al. Toxicity and antioxidant activity in vitro and in vivo of two Fucus vesiculosus extracts. J Agric Food Chem. 2008;56(17):7773-7780.
21. Veena CK, Josephine A, Preetha SP, Varalakshmi P. Physico-chemical alterations of urine in experimental hyperoxaluria: a biochemical approach with fucoidan. J Pharm Pharmacol. 2007;59(3):419-427.
22. Angulo Y, Lomonte B. Inhibitory effect of fucoidan on the activities of crotaline snake venom myotoxic phospholipases A(2). Biochem Pharmacol. 2003;66(10):1993-2000.
23. + cells. Exp Hematol. 2007;35(6):989-994.
24. Irhimeh MR, Fitton JH, Lowenthal RM. Pilot clinical study to evaluate the anticoagulant activity of fucoidan. Blood Coagul Fibrinolysis. 2009;20(7):607-610.
25. Li N, Zhang Q, Song J. Toxicological evaluation of fucoidan extracted from Laminaria japonica in Wistar rats. Food Chem Toxicol. 2005; 43:421-426.
26. Gideon TP, Rengasamy R. Toxicological evaluation of fucoidan from Cladosiphon okamuranus. J Med Food. 2008;11(4):638-642.
27. Brooks LO, Rolfe MI, Cheras PA, Myers SP. The comprehensive osteoarthritis test: a simple index for measurement of treatment effects in clinical trials. J Rheumatol. 2004;31(6):1180-1186.
28. Dubois MGK, Hamilton JK, Rebers PA, Smith F. Colorimetric methods for determination of sugars and related substances. Anal Chem. 1956; 28(3):350-356.
29. Snijders TAB, Bosker RJ. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modelling. London, UK: Sage Publications; 1999.
30. Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007;5(1): 19-34.
31. Hulejova H, Baresova V, Klezl Z, Polanska M, Adam M, Senolt L. Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine. 2007;38(3):151-156.
32. Machelska H, Cabot PJ, Mousa SA, Zhang Q, Stein C. Pain control in inflammation governed by selectins. Nat Med. 1998;4(12): 1425-1428.